Perigon Wealth Management LLC trimmed its position in shares of Becton Dickinson and Co (NYSE:BDX) by 19.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,636 shares of the medical instruments supplier’s stock after selling 402 shares during the quarter. Perigon Wealth Management LLC’s holdings in Becton Dickinson and were worth $391,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Street Corp boosted its stake in shares of Becton Dickinson and by 0.3% during the first quarter. State Street Corp now owns 11,490,473 shares of the medical instruments supplier’s stock valued at $2,640,166,000 after purchasing an additional 39,890 shares during the period. Wellington Management Group LLP boosted its stake in shares of Becton Dickinson and by 225.4% during the first quarter. Wellington Management Group LLP now owns 8,473,220 shares of the medical instruments supplier’s stock valued at $1,946,892,000 after purchasing an additional 5,869,236 shares during the period. Morgan Stanley boosted its stake in shares of Becton Dickinson and by 1.0% during the first quarter. Morgan Stanley now owns 5,901,391 shares of the medical instruments supplier’s stock valued at $1,355,965,000 after purchasing an additional 55,633 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Becton Dickinson and by 27.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 4,086,572 shares of the medical instruments supplier’s stock valued at $938,970,000 after purchasing an additional 885,564 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Becton Dickinson and by 1.5% during the first quarter. Geode Capital Management LLC now owns 3,746,371 shares of the medical instruments supplier’s stock valued at $858,916,000 after purchasing an additional 54,129 shares during the period. 85.44% of the stock is owned by institutional investors.
BDX opened at $281.34 on Friday. Becton Dickinson and Co has a 52-week low of $197.75 and a 52-week high of $286.72. The company has a quick ratio of 0.66, a current ratio of 0.98 and a debt-to-equity ratio of 0.80. The company has a market cap of $76.29 billion, a P/E ratio of 84.74, a price-to-earnings-growth ratio of 3.74 and a beta of 0.93. The firm’s 50-day moving average price is $250.93 and its 200-day moving average price is $250.95.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.32 by $0.23. Becton Dickinson and had a net margin of 6.10% and a return on equity of 15.75%. The firm had revenue of $4.25 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the company posted $2.59 earnings per share. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. On average, research analysts anticipate that Becton Dickinson and Co will post 10.35 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a $0.79 dividend. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $3.16 dividend on an annualized basis and a yield of 1.12%. Becton Dickinson and’s dividend payout ratio is currently 27.05%.
In related news, EVP Patrick Kaltenbach sold 1,049 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $243.20, for a total value of $255,116.80. Following the sale, the executive vice president now owns 12,661 shares in the company, valued at $3,079,155.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.12% of the stock is owned by corporate insiders.
Several research firms recently weighed in on BDX. Wells Fargo & Co restated a “buy” rating on shares of Becton Dickinson and in a report on Friday, May 8th. Zacks Investment Research downgraded Becton Dickinson and from a “hold” rating to a “sell” rating and set a $245.00 price objective for the company. in a report on Wednesday, May 27th. Stifel Nicolaus lifted their price objective on Becton Dickinson and from $265.00 to $280.00 and gave the company a “buy” rating in a report on Friday, May 8th. SVB Leerink lifted their price objective on Becton Dickinson and from $262.00 to $277.00 and gave the company a “market perform” rating in a report on Wednesday, July 15th. Finally, Barclays upgraded Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $300.00 price objective for the company in a report on Thursday, July 9th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Becton Dickinson and has an average rating of “Hold” and an average price target of $275.06.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
See Also: How to invest in a bear market
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.